1Renal Data System.USRDS 1998 annual data report [C].Bethesda,Md:National Institute of Diabetes and Digestive Kidney Disease,1998:39 (NIH publication no.98-3176).
2MERION R M,WHITE D J,THIRU S,et al.Cyclosporine:five year's experience in cadaveric renal transplantation[J].N Engl J Med JT-The New England Journal of Medicine,1984,310:148-154.
3SEHGAL S N.Sirolimus:its discovery,biological properties,and mechanism of action [J].Transplant Proc,2003,35 (Suppl):7S-14S.
4MORRIS R E.Rapamycins:antifungal,antitumor,antiproliferative and immunosuppressivemacrolides [J].Transplant Rev,1992:639-687.
5STEPKOWSKI S M.Preclinical results of sirolimus treatment in transplant models [J].Transplant Proc,2003,35:219S-226S.
6ANDOH T F,BURDMANN E A,FRANSECHINI N,et al.Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506 [J].Kidney Int,1996,50:1110-1117.
7YOSHIMURA R,YOSHIMURA N,OHYAMA A,et al.The effect of immunosuppressive agents (FK-506,rapamycin) on renal P450 systems in rat models [J].J Pharm Pharmacol,1999,51:941-948.
8NIELSEN F T,OTTOSEN P,STARKLIMT H,et al.Kidney function and morphology after short-term combination therapy with cyclosporine A,tacrolimus and sirolimus in the rat[J].Nephrol Dial Transplant,2003,18:491-496.
9MOON J I,KIM Y S,KIM M S,et al.Effect of cyclosporine,mycophenolic acid,and rapamycin on the proliferation of rat aortic vascular smooth muscle cells:in vitro study [J].Transplant Proc,2000,32:2026-2027.
10MARKS A R.Rapamycin:signaling in vascular smooth muscle [J].Transplant Proc,2003,35:231S-233S.
